NEW YORK – Stilla Technologies and Promega said on Wednesday that they have signed a comarketing deal for Promega's Maxwell systems for nucleic acid extraction and Stilla's six-color Naica digital PCR system and will offer a workflow for different applications.
The firms plan to present data related to the workflow, which could be used for liquid biopsy testing, sentinel pathogen testing, infectious disease assays, and drug discovery, at the upcoming American Association for Cancer Research meeting.
"The strategic partnership with Promega enhances our value proposition by bringing a fully validated sample-to-answer solution for biomarker testing," Philippe Mourère, president and CEO of Stilla Technologies, said in a statement.
"This new end-to-end solution, pairing the Maxwell system with the Naica system, will facilitate the move of high multiplex genomic signatures from liquid biopsies, typically performed through NGS in centralized labs, to decentralized testing," said Tom Livelli, Promega's VP of life sciences products and services.